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Abstract Acquired resistance to glycopeptides in enterocoeci is associated with the production of D-Akinine: D-Alanme Iigase-related proteins. The 
VanA protein associated with high-level vancomycin and teicoplanin resistance (VanA phenotype) synthesizes a new peptidoglycau precursor, 
D-alanine-n-lactate, that has reduced glycopeptide atlinity. Production of a similar protein, VanB, is induced in strains that display variable levels 
of vancomycin resistance but remain susceptible to teicoplanin (VanB phenotype). This paper describes the over-production, purification and 
characterization of VanB. Comparison of kinetic parameters of the two Van enzymes uggests that differences in catalytic efficiency could account, 
at least in part, for the various levels of vaucomycin resistance. 
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1. Introduction 
The C-terminal D-Ah-D-hi residues of bacterial cell wall 
precursors are the target for glycopcptide antibiotics, such as 
vancomycin and teicoplanin, which inhibit the transglycosyla- 
tion and transpeptidation reactions of peptidoglycan assembly 
[ 151. Three decades after introduction of vancomycin in human 
therapy the first resistant clinical isolates of Enterococcus were 
detected [l 11. 
In enterococci at least one protein is produced in association 
with one of the three glycopeptide resistance phenotypes 
(VanA, VanB and VanC) [ 11. Isolates with high-level resistance 
to vancomycin (MIC from 64 to l,OOO,&ml) and to teicoplanin 
(MIC from 16 to 512 ,@ml) belong to the Van4 phenotype. 
This inducible resistance is associated with production of the 
VanA protein, a D-Ala: D-Ala ligase of altered substrate speci- 
ficity which preferentially catalyzes ester bond formation be- 
tween D-Ala and a D-Zhydroxyacid [5,6]. D-Lactate (D-Lac) was 
identified as the in vivo substrate for VanA [2,10]. The dep- 
sipeptide D-Ala-D-Lac synthesized by VanA is incorporated 
into the cell wall by the usual pathway of peptidoglycan biosyn- 
thesis. The low affinity of glycopeptides for the modified ccl1 
wall precursors allows peptidoglycan synthesis in the presence 
of the antibiotics [l]. In addition to VanA, four proteins are 
required for inducible vancomycin resistance: the VanH dehy- 
drogenase for synthesis of D-Lac [ 11; VanX, a dipeptidase which 
hydrolyses D-Ala-D-Ala [ 161; and VanR-Vans, a two-compo- 
nent regulatory system [3,19]. Strains of E. fuecium and 
E. faecalis which display variable levels of inducible resistance 
to vancomycin (MIC from 4 to 1,000 &ml) and retain 
susceptibility to teicoplanin (MIC < 2 @ml) are of the VanB 
type [14,18]. The VanC phenotype corresponds to constitutive 
low-level resistance to vancomycin alone (MIC from 2 to 32 
,ug/ml) and is found in E. casselifavus, E. jlavescens and 
E. gallinarum [8,12]. The vanB and vanC genes encode two 
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proteins, VanB and VanC, that are structurally related to VanA 
and to D-Ala:D-Ala ligases [8,9]. Analysis of the peptidoglycan 
composition of VanB and VanC type strains allowed identifica- 
tion of D-Lac and D-serine, respectively, as C-terminal residues 
of peptidoglycan precursors [4,9,17]. These observations imply 
that VanB and VanC are also o-Ala:D-Ala ligases of altered 
substrate specificity. 
Since differences in specificity and catalytic efficiency of the 
Van proteins could account for the three phenotypes detected 
so far, we compared the kinetic parameters of the purified 
proteins. In this report, we describe overproduction, puritica- 
tion and kinetic characterization of the VanB protein of 
E. faecalis V583. 
2. Experimental 
2.1. Construction of plasmid pAT204 for over-production of the 
VanB protein 
The 3.3-kb KpnI-Hind111 insert of pAT202 [9], containing the vanB 
gene of E. faecalis V583. was cloned into the SmaI site of pUC19 using 
a commercial DNA blunting kit (Amersham). A plasmid with vanB and 
the lac promoter in the same orientation that allows control of vanB 
expression was selected for further studies. Two deletions were intro- 
duced to prevent expression of the genes flanking van& (i) the region 
upstream from vanB was deleted by exonuclease III-S1 nuclease diges- 
tion (Erase-a-Base, Promega) leaving 244 bp upstream from the ATG 
start codon: (ii) the fragment between the SspI site 288 bp downstream 
from the TGA stop eodon and the unique SspI site of pUC19 was 
excised to remove the region downstream from vanB. The resulting 
plasmid, designated pAT204, allows expression of the vanB gene under 
control of the lac promoter. 
2.2. Over-production and purification of VanB 
All the purification steps were Performed at 4’C. Enzyme activity 
was monitored by thin-layer chromatographic assay [5] or, when possi- 
ble, by the ADP release coupled assay [7’J Protein concentration was 
determined by measurement of the absorbance at 280 nm. 
Plasmid pAT204 was transformed into Escherichia coli HBlOl and 
a transformant was grown at 37°C in 5 1 of Luria broth (LB) containing 
ampicillin (100 &ml) to an absorbance of 0.6 at 600 nm. Production 
of VanB was induced by addition of isopropylthiogalactoside to a final 
concentration of 1 mM. Cells were then grown for 3 h and harvested 
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by centrifugation at 8000 x g for 15 min. The cell pellet (20 g) was 
suspended in 50 ml of 50 mM HEPES (pH 7.5) containing 5 mM MgCl,, 
1 mM EDTA and 5 mM DTT and was disrupted with a Branson 
SoniIier-250 sonicator. Cell debris were removed by centrifugation at 
25,000 x g for 30 min. 
The supematant was loaded onto a Q-sepharose Fast-flow column 
(50 ml) (Pharmacia) equilibrated with HEPES 50 mM @H 7.5) contain- 
ing 5 mM MgCl,, 1 mM EDTA and 1 mM DTT. The column was eluted 
in two steps, first at 100 mM and then at 300 mM NaCl. VanB was 
recovered at 300 mM. The active fractions were pooled and concen- 
trated using an ultrafiltration device (Novacell, Filtron) equipped with 
a 10K membrane. The concentrated pool (10 ml) was passed twice 
through a 2 ml ATP-OH ribose attachment-agarose column (Sigma) at 
a flow rate of 25 ml/h, until no ATP-ase activity was detected in the 
solution using the ADP release coupled assay [7] without addition of 
D-alanine. 
2.3. Substrate specijicity and kinetic analysis of VanB 
Substrate specificity was assayed by thin-layer chromatographic 
(TLC) assay [6]. The kinetic parameters of VanB for o-Ala: o-Ala ligase 
activity were determined using the equation: 
previously established by Neuhaus [13] where K*, and K,+ are the 
Michaelis constants of, respectively, the first (N-terminal) and the sec- 
ond (C-terminal) alanine residues, and [A] is D-Ala concentration. 
& values were calculated by fitting the data obtained by the spectro- 
photometric assay described by Daub et al. [q to the above equation 
using the Enzfitter programme. Kinetic parameters for the D-Ala: D-Z- 
hydroxyacid synthase activity were determined at 5 mM of D-Ala. 
D-Ala-D-hydroxyacid was separated from D-Ala-D-Ala by TLC on cel- 
lulose using I-[WJD-Ala (40 mCi/mmol) and the amount of the dep- 
sipeptide formed was determined by radioactivity counting. In the case 
of D-Ala-D-Lac synthesis, 1-[i4C]o-lactate (50 mCi/mmol) was used in- 
stead of l-[‘%$&la since D-Ala-D-Lac co-migrates with D-Ala-D-Ala 
in the assay conditions [6]. The K,,, for D-hydroxyacid was calculated 
according to the equation: 
K 
v= (2) 
as described by Neuhaus [13], where KA, and 4, have the same signif- 
icance given in eq. 1; KB and [Bj are, respectively, the Michaelis constant 
and concentration of the D-hydroxyacid under assay. ATP was used at 
saturating concentration of 10 mM. 
Table 2 
Kinetic properties of VanB and VanA as o-Ala-D-2-hydroxyacid ligases 
D-Ah-D-X VanB VanAa 
o-Ala-D-2-hydroxybutyrate KA, (mM) ndb 4.1 
KS (mM) 3.0 + 0.28d 0.6 (0.5 f 0.09)c 
k,, (min-‘) 15 f 1.2 108 (78 f 8.6) 
k,tlEcm (M-l s-‘) 83.6 f 16.1 3000 (2866 f 308) 
o-Ala-o-2-hydroxyvalerate KA, @W nd nd 
KB (mM) 8.3 + 0.26 2.3 
k,, (min-‘) 25 + 2.5 156 
k,,JK, (M-l. s-‘) 50.2 + 5.3 810 
D-Ala-o-lactate KA, (mM) nd 3.2 
KS (mM) 11.4 f 1 7.1 
k,, (mm-‘) 28.2 f 1.6 94 
k,JK,,, (M-l . s-l) 41.4 f 2.4 220 
KA, and KB refer to the Michaelis constants for the binding of, respectively, D-Ala and o-hydroxyacid. 
’ Data from [5]. 
b nd = not determined. 
“Values in parentheses are calculated with purified VanA from E. coli HBlOUpAT219 (Dutka-Malen et al., unpublished). 
d Mean of three determinations. 
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Table 1 
Kinetic properties of VanB and Van4 as D-Ala-D-Ala ligases 
Substrate/product VanB VanA” 
o-Ala-D-Ala &, (mM) 1.2 f 0.4b 3.4 
KA~@W 34 + 1.1 38 
kat (mm-‘) 246 + 2.0 295 
k-J& (M-l . s-‘) 12Ok4.1 129 
ATP G 01M) 69 + 2.1 116 
KA and KA refer to the Michaelis constants for the binding of, respec- 
tiv&y, the l&t (N-terminal) and second (C-terminal) residues. 
*Data from 15). 
b Mean of three determinations. 
3. Results and discussion 
The VanB protein was over-produced to ca. 10% of the 
soluble proteins of E. coli HBlOl harboring recombinant plas- 
mid pAT204. The enzyme was detected uring purification by 
its ability to synthesize u-Ala-D-2-hydroxybutyrate by TLC. A 
two-step purification of VanB, including Q-Sepharose anion- 
exchange chromatography and ATP-agarose affinity chroma- 
tography, was devised. Stepwise elutions at 100 mM and 300 
mM NaCl from Q-Sepharose allowed vanB protein recovery in 
the high salt eluent. Unlike VanA [5], VanB was found to 
aggregate upon ammonium sulfate fractionation, suggesting a 
difference in hydrophobic surface pattern. ATP-agarose 
chromatography was finally used to eliminate contaminating 
ATPase activity which interfered with the n-Ala:p-Ala ligase 
ADP release coupled assay. SDS-PAGE displayed a single 
band at 38 kDa (data not shown). Starting from 20 g of wet 
cells, this two-step purification procedure yielded 30 mg 
of VanB protein with a specific activity of 11 U/mg. A frac- 
tion of the ATP-agarose eluate was subjected to sequence anal- 
ysis. The N-terminal sequence (M-N-K-I-K-V-A-I-I-F-G) 
determined on 11 Edman degradation cycles was identical 
with that deduced from the nucleotide sequence [9]. No 
contaminating sequence could be detected from HPLC anal- 
ysis of PTH-amino acids, suggesting a high degree of protein 
purity. 
Like VanA [5,6], VanB was found to possess D-Ala:D-Ala 
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ligase activity. Despite slight differences in K,,, and k,, values, 
the catalytic efficiencies of the two enzymes for D-Ala-D-Ala 
synthesis were similar (Table 1). The substrate specificity of 
VanB for amino acids was studied by TLC analysis of radioac- 
tive dipeptides produced following incubation of [i4C]D-Ala (0.2 
mM) with 10 mM of the amino acid. Qualitatively, VanB was 
able to synthesize mixed dipeptides with hydrophobic o-amino 
acids such as n-phenylalanine, o-methionine, D-valine, 
o-neurleucine, n-isoleucine. KY,,, values of VanB for n-hydroxy- 
acids were determined at saturating concentrations of o-Ala 
and ATP, respectively, 5 and 10 mM, and were found to be 2- 
to 5-fold higher (Table 2) than those of VanA [6]. D-2-Hy- 
droxybutyrate was the best substrate with a K,,, of 3 mM, lower 
than those for o-Lac (11.4 mM) and n-Zhydroxyvalerate (8.3 
mM). As found for VanA [6], these results indicate the longer 
side chain preference of VanB. Furthermore, catalytic efficien- 
cies (k-J&,) of the o-hydroxyacids tested for VanB were 5- to 
35-times lower than those for VanA (Table 2). 
Our results demonstrate that VanB is a depsipeptide synthase 
displaying a substrate specificity similar to that of VanA [5,6]. 
This is not surprising given the extensive similarity (76% amino 
acid identity) between VanA and VanB [9] and the identifica- 
tion of o-Lac as in vivo substrate for both enzymes [9,10]. The 
catalytic efficiency for depsipeptide synthesis of VanB is lower 
than that of VanA (Table 2). Therefore, low-level resistance to 
vancomycin of E. faecalis V583 (MIC = 64 @ml) might be 
related to synthesis of smaller amounts of cell wall precursors 
terminating in o-Lat. However, a lower level of production or 
activity of other enzymes required for resistance (n-2-hydroxy- 
acid dehydrogenase, dipeptidase), as well as a lower VanB 
concentration, could also contribute to the difference in expres- 
sion of vancomycin susceptibility. Finally, a difference in spec- 
ifkity between the two-component regulatory systems for ex- 
pression of the vad [3] and vanB (Evers et al., unpublished 
data) gene clusters could account for the fact that VanB strains 
remain susceptible to teicoplanin, since this antibiotic is not an 
inducer. 
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